Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: Prospective clinical and MRI follow-up study

Achiron, 2000, Multiple sclerosis — from probable to definite diagnosis: a 7-year prospective study, Arch. Neurol., 57, 974, 10.1001/archneur.57.7.974 Afzali, 2010, Translational mini-review series on Th17 cells: induction of interleukin-17 production by regulatory T cells, Clin. Exp. Immunol., 159, 120, 10.1111/j.1365-2249.2009.04038.x Aktas, 2006, Death ligands and autoimmune demyelination, Neuroscientist, 12, 305, 10.1177/1073858405285208 Barkhof, 2002, The clinico-radiological paradox in multiple sclerosis revisited, Curr. Opin. Neurol., 15, 239, 10.1097/00019052-200206000-00003 Bernhagen, 2007, MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment, Nat. Med., 13, 587, 10.1038/nm1567 Bonetti, 1997, Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis, Ann. Neurol., 42, 74, 10.1002/ana.410420113 Boylan, 2001, Serum and cerebrospinal fluid soluble Fas levels in clinical subgroups of multiple sclerosis, Immunol. Lett., 78, 183, 10.1016/S0165-2478(01)00244-9 Bradl, 2009 Brex, 2002, A longitudinal study of abnormalities on MRI and disability from multiple sclerosis, N. Engl. J. Med., 346, 158, 10.1056/NEJMoa011341 Calandra, 1994, The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor, J. Exp. Med., 179, 1895, 10.1084/jem.179.6.1895 Cannella, 2007, Multiple sclerosis: death receptor expression and oligodendrocyte apoptosis in established lesions, J. Neuroimmunol., 188, 128, 10.1016/j.jneuroim.2007.05.018 Cepok, 2009, Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis, Arch. Neurol., 66, 1216, 10.1001/archneurol.2009.138 Ciusani, 1998, Soluble Fas (Apo-1) levels in cerebrospinal fluid of multiple sclerosis patients, J. Neuroimmunol., 82, 5, 10.1016/S0165-5728(97)00177-X Comi, 2000, Defective T cell fas function in patients with multiple sclerosis, Neurology, 55, 921, 10.1212/WNL.55.7.921 Denkinger, 2003, In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system, J. Immunol., 170, 1274, 10.4049/jimmunol.170.3.1274 Dowling, 1996, Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain, J. Exp. Med., 184, 1513, 10.1084/jem.184.4.1513 D'Souza, 1996, Multiple sclerosis: Fas signaling in oligodendrocyte cell death, J. Exp. Med., 184, 2361, 10.1084/jem.184.6.2361 Fassbender, 1998, Increased release of interleukin-12p40 in MS: association with intracerebral inflammation, Neurology, 51, 753, 10.1212/WNL.51.3.753 Fisniku, 2008, Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis, Brain, 131, 808, 10.1093/brain/awm329 Fox, 2008, Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury, Mult. Scler., 14, 1036, 10.1177/1352458508092261 Frischer, 2009, The relation between inflammation and neurodegeneration in multiple sclerosis brains, Brain, 132, 1175, 10.1093/brain/awp070 Harris, 2009, Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making, Mol. Diagn. Ther., 13, 225, 10.1007/BF03256329 Hawker, 2009, Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial, Ann. Neurol., 66, 460, 10.1002/ana.21867 Heinonen, 1998, Semi-automatic tool for segmentation and volumetric analysis of medical images, Med. Biol. Eng. Comput., 36, 291, 10.1007/BF02522473 Heinonen, 1998, Applicability of semi-automatic segmentation for volumetric analysis of brain lesions, J. Med. Eng. Technol., 22, 173, 10.3109/03091909809032536 Hohnoki, 1998, Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage, J. Neuroimmunol., 87, 27, 10.1016/S0165-5728(98)00053-8 Imitola, 2005, Cytokines in multiple sclerosis: from bench to bedside, Pharmacol. Ther., 106, 163, 10.1016/j.pharmthera.2004.11.007 Kithcart, 2010, A small-molecule inhibitor of macrophage migration inhibitory factor for the treatment of inflammatory disease, FASEB J., 24, 4459, 10.1096/fj.10-162347 Kurtzke, 1983, Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, 33, 1444, 10.1212/WNL.33.11.1444 Lassmann, 2007, The immunopathology of multiple sclerosis: an overview, Brain Pathol., 17, 210, 10.1111/j.1750-3639.2007.00064.x Lopatinskaya, 2006, Mediators of apoptosis Fas and FasL predict disability progression in multiple sclerosis over a period of 10years, Mult. Scler., 12, 704, 10.1177/1352458506070826 Mahad, 2003, The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE), Semin. Immunol., 15, 23, 10.1016/S1044-5323(02)00125-2 McDonald, 2001, Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, Ann. Neurol., 50, 121, 10.1002/ana.1032 McFarland, 2009, Examination of the role of magnetic resonance imaging in multiple sclerosis: a problem-orientated approach, Ann. Indian. Acad. Neurol., 12, 254, 10.4103/0972-2327.58284 McQualter, 2007, Multiple sclerosis: a battle between destruction and repair, J. Neurochem., 100, 295, 10.1111/j.1471-4159.2006.04232.x Niino, 2000, Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behcet's disease, J. Neurol. Sci., 179, 127, 10.1016/S0022-510X(00)00397-X Pender, 2007, Treating autoimmune demyelination by augmenting lymphocyte apoptosis in the central nervous system, J. Neuroimmunol., 191, 26, 10.1016/j.jneuroim.2007.09.015 Petereit, 2003, Low interleukin-10 production is associated with higher disability and MRI lesion load in secondary progressive multiple sclerosis, J. Neurol. Sci., 206, 209, 10.1016/S0022-510X(02)00420-3 Polman, 2005, Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”, Ann. Neurol., 58, 840, 10.1002/ana.20703 Rinta, 2008, Apoptosis-related molecules in blood in multiple sclerosis, J. Neuroimmunol., 205, 135, 10.1016/j.jneuroim.2008.09.002 Sellebjerg, 2009, Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation, Eur. J. Neurol., 16, 1291, 10.1111/j.1468-1331.2009.02716.x Selmaj, 1991, Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions, J. Clin. Invest., 87, 949, 10.1172/JCI115102 Sharief, 2000, Impaired Fas-independent apoptosis of T lymphocytes in patients with multiple sclerosis, J. Neuroimmunol., 109, 236, 10.1016/S0165-5728(00)00325-8 Sharief, 1991, Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis, N. Engl. J. Med., 325, 467, 10.1056/NEJM199108153250704 Sospedra, 2005, Immunology of multiple sclerosis, Annu. Rev. Immunol., 23, 683, 10.1146/annurev.immunol.23.021704.115707 Szczucinski, 2007, Chemokines and chemokine receptors in multiple sclerosis, Potential targets new therapies. Acta Neurol. Scand., 115, 137, 10.1111/j.1600-0404.2006.00749.x Tomassini, 2009, Multiple sclerosis lesions: insights from imaging techniques, Expert Rev. Neurother., 9, 1341, 10.1586/ern.09.83 Tumani, 2009, Cerebrospinal fluid biomarkers in multiple sclerosis, Neurobiol. Dis., 35, 117, 10.1016/j.nbd.2009.04.010 Watzlawik, 2010, Importance of oligodendrocyte protection, BBB breakdown inflammation remyelination. Expert Rev. Neurother, 10, 441, 10.1586/ern.10.13 Zipp, 2000, Apoptosis in multiple sclerosis, Cell Tissue Res., 301, 163, 10.1007/s004410000179 Zipp, 1998, Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing–remitting multiple sclerosis, Ann. Neurol., 43, 116, 10.1002/ana.410430120